ADDITIONAL TESTING
Additional Testing
We have created a platform for the development of new tests to help researchers commercialize their interests.
Tempus is partnering with researchers to bring their predictive diagnostic tests to the clinic. We can leverage our molecular and clinical data, CAP/CLIA lab, and clinician network to create algorithms developed in the research setting to help treat cancer patients.
These tests can predict which patients are at higher risk, and therefore might benefit from adjuvant therapy, as well as other endpoints that can positively impact a patient’s journey.
HRD TEST
The Tempus Homologous Recombination Deficiency (HRD) test is a DNA-based test, available as part of the xT platform, for clinicians aiming to better understand if their patient has Homologous Recombination Deficiency. Tempus HRD is a comprehensive view into a patient’s ability to repair double-stranded DNA breaks. HRD status can be used to identify patients who may be sensitive to PARP inhibitors and/or platinum-based chemotherapy.
The Tempus HRD test takes into account results from our xT Sequencing Panel, giving a full view into 18 commonly mutated genes in the HR-pathway, along with a genome wide loss-of-heterozygosity (LOH) score, giving a clinician one of the most complete views of HRD status on the market. The HRD test can be ordered with 6 major cancer subtypes: Ovarian, Breast, Pancreatic, Prostate, Non-small-cell lung cancer, and Glioblastoma, and does not require additional tissue from the patient.
The Tempus HRD advantages:
- Identify the right patients for therapy
- Less tissue, less work
TO TEST
The Tempus Tumor Origin (TO) test uses information from analysis of nucleic acids by next-generation sequencing (NGS) performed as part of a separately-ordered Tempus|xT test. The Tempus TO test was built using a large internal database of annotated tumor molecular data. The TO test uses tumor RNA expression results to indicate the most likely primary cancer subtype and other potentially likely subtypes of a tumor specimen from 64 possible diagnostic subtypes.
The intended use of the TO test is for cancers of unknown primary (CUPs) and other tumors of uncertain origin and may help clinicians make more informed decisions where other clinical information like imaging and immunohistochemistry results do not provide a definitive diagnosis.
When paired with xT, the TO results may provide insight into the tumor’s diagnosis and site of origin that may be used to guide patient care and clinical trial eligibility.
